Orbidex T

Orbidex T0.1%+0.3%

Ophthalmic Ointment

Dexamethasone + Tobramycin

Popular Pharmaceuticals Ltd.

Product Code : 12663
MRP 90.00
10% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of Orbidex T 0.1%+0.3%

This sterile Eye Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.

Theropeutic Class

Ophthalmic steroid - antibiotic combined preparations

Pharmacology

Like other amino-glycosides, the bactericidal activity of Tobramycin is accomplished by specific inhibition of normal protein synthesis in susceptible bacteria, but at the present time, very little is known about this action. It is thought that inhibition of protein synthesis is due to an action on ribosome that causes bacterial misreading of messenger RNA. The action of Dexamethasone is to inhibit the phospholipase A2, the first step in prostaglandin synthesis. Also Dexamethasone inhibits the chemo-tactic infiltration of neutrophils into the site of inflammation. The result is that its anti-inflammatory activity is 25 times greater and its overall therapeutic effectiveness 8-10 times greater than that of hydrocortisone.

Dosage & Administration of Orbidex T 0.1%+0.3%

Insert 1 drop into the conjunctival sac 3-5 times per day. During the initial 24 to 48 hours, the dosage may be increased to 1 drop every 2 hours.

Dosage of Orbidex T 0.1%+0.3%

Insert 1 drop into the conjunctival sac 3-5 times per day. During the initial 24 to 48 hours, the dosage may be increased to 1 drop every 2 hours.

Interaction of Orbidex T 0.1%+0.3%

No specific interaction studies were performed with this combination eye drops. In case of concomitant therapy with other topical ophthalmic medicines, an interval of 10 minutes should be allowed between successive applications.

Contraindications

Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and other viral disease of the cornea and conjunctiva. Mycobacterial infections of the eye caused by, but not limited to, acid-fast bacilli such as Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium avium. Fungal diseases of ocular structures. Untreated purulent infection of the eye. Hypersensitivity to any component of the medication.

Side Effects of Orbidex T 0.1%+0.3%

The most frequent side effects to topical ocular Tobramycin are localized ocular toxicity and hypersensitivity, including lid itching and swelling and conjuntival erythema. The reactions due to the steroid component are elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsule cataract formation.

Pregnancy & Lactation

Safety for use during pregnancy and lactation in humans has not been established

Precautions & Warnings

Shake the bottle well before use. To prevent contamination do not touch the tip of the bottle to affected eye, eyelid or any surface of of the affected eye. Keep the bottle tightly closed after use.

Overdose Effects of Orbidex T 0.1%+0.3%

Overdose of this eye drops may be flushed from the eye(s) with lukewarm tap water.

Storage Conditions

Store at room temperature. Close the bottle immediately after use. Do not use for longer than one month after opening the bottle.

Use In Special Populations

Use in paediatric: Safety and effectiveness in paediatric patients below 2 years have not been established.

Drug Classes

Ophthalmic steroid - antibiotic combined preparations

Mode Of Action

Like other amino-glycosides, the bactericidal activity of Tobramycin is accomplished by specific inhibition of normal protein synthesis in susceptible bacteria, but at the present time, very little is known about this action. It is thought that inhibition of protein synthesis is due to an action on ribosome that causes bacterial misreading of messenger RNA. The action of Dexamethasone is to inhibit the phospholipase A2, the first step in prostaglandin synthesis. Also Dexamethasone inhibits the chemo-tactic infiltration of neutrophils into the site of inflammation. The result is that its anti-inflammatory activity is 25 times greater and its overall therapeutic effectiveness 8-10 times greater than that of hydrocortisone.

Pregnancy

Safety for use during pregnancy and lactation in humans has not been established

Pediatric Uses

Use in paediatric: Safety and effectiveness in paediatric patients below 2 years have not been established.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.